Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Supports J&J’s Antibiotic Doribax With Votes, Not Confidence

Executive Summary

An FDA panel's votes on July 16 to support Johnson & Johnson's Doribax (doripenem) reflected more the difficulty of new antibiotic drug development than the merits of J&J's particular application

You may also be interested in...



‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly

Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.

Antibiotic Non-Inferiority Trials To Be Addressed By FDA Advisory Committee

Antibiotic drug sponsors may get more clarity on FDA's policy for non-inferiority margins following the conclusion of a three-day Anti-Infective Drugs Advisory Committee meeting in November

Antibiotic Non-Inferiority Trials To Be Addressed By FDA Advisory Committee

Antibiotic drug sponsors may get more clarity on FDA's policy for non-inferiority margins following the conclusion of a three-day Anti-Infective Drugs Advisory Committee meeting in November

Related Content

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel